Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYK52O)

Drug Name
LHC165 Drug Info
Synonyms
LHC-165; 1258595-14-0; 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid; UNII-RD02U4QLM1; RD02U4QLM1; SCHEMBL174281; US9597326, Compound 20; BDBM301804; NSC819211; s8838; NSC-819211; HY-111786; CS-0091872; 3-(5-amino-2-(4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid; Benzo(F)(1,7)naphthyridine-8-propanoic acid, 5-amino-2-(2-(4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2-methylphenyl)ethyl)-
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
49838259
CAS Number
CAS 1258595-14-0
TTD Drug ID
DMYK52O

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Toll-like receptor 7 (TLR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imiquimod DM1TMA3 Alopecia areata ED70.2 Approved [3]
Hydroxychloroquine DMSIVND Chronic renal failure GB61.Z Approved [4]
ANA773 DMSC8YW Hepatitis C virus infection 1E51.1 Phase 2a [5]
GS-9620 DMG5C8D Hepatitis B virus infection 1E51.0 Phase 2 [6]
IMO-3100 DMM549D Psoriasis vulgaris EA90 Phase 2 [7]
Resiquimod DML6XSP Actinic keratosis EK90.0 Phase 2 [8]
LOXORIBINE DMIV9ZE Immune System disease 4A01-4B41 Phase 2 [9]
GSK2245035 DMBWPZJ Asthma CA23 Phase 2 [10]
AZD-8848 DM0M7QW Allergic rhinitis CA08.0 Phase 2 [11]
Isatoribine DMHOJ8W Hepatitis C virus infection 1E51.1 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 7 (TLR7) TTRJ1K4 TLR7_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT03301896) Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
2 Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020 May 1;193:112238.
3 Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
4 TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
5 Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
6 Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
7 Company report (Iderapharma)
8 TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
9 The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
10 Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
11 Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
12 Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.